We are live on
!
Find out more
TCM
Tao Capital Management Portfolio holdings
AUM
$119M
1-Year Est. Return
87.46%
This Fund
S&P 500
This Quarter
Est. Return
+3.81%
1 Year Est. Return
+87.46%
3 Year Est. Return
+356.21%
5 Year Est. Return
+280.73%
10 Year Est. Return
–
AUM
$116M
AUM Growth
-$16M
(-12%)
Cap. Flow
-$17.8M
Cap. Flow
% of AUM
-15.32%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
–
Reduced
2
Closed
2
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$10.2M |
| 2 |
Ouster
OUST
|
+$7.4M |
| 3 |
SOND
Sonder
SOND
|
+$102K |
| 4 |
Ginkgo Bioworks
DNA
|
+$82.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 43.05% |
| 2 | Healthcare | 41.21% |
| 3 | Technology | 15.75% |
Similar funds
SF
MWM
VA
HPM
SKK
WKSWA
CA
LC
Tao Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, Tao Capital Management held 10 positions worth $116M, down 12% from $132M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Tao Capital Management withdrew a net $17.8M in Q4 2025, closing 2 positions and reducing 2 holdings. Its most notable exit was Sonder, an estimated $102K position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 43% of assets, up from 37% a quarter earlier, followed by Healthcare and Technology.
- Tao Capital Management's biggest Q4 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $10.2M.
- Tao Capital Management fully exited Sonder in Q4 2025, selling an estimated $102K.
- Tao Capital Management's ten largest holdings make up 100% of its $116M portfolio in Q4 2025.
- Tao Capital Management opened 0 new positions and closed 2 in Q4 2025.
- Tao Capital Management's portfolio value fell 12% quarter-over-quarter to $116M.
Based on Tao Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.